PI3K is required for the physical interaction and functional inhibition of NF-κB by β-catenin in colorectal cancer cells

Biochemical and Biophysical Research Communications

Volumn 434, Issue 4, 2013, Pages 760-766

  Liu, Jingyi ^a,b   Liao, Yueling ^b   Ma, Kewei ^c   Wang, Yonglu ^c   Zhang, Guoxiang ^d   Yang, Rongcun ^a   Deng, Jiong ^b,e  

^a NANKAI UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c JILIN UNIVERSITY   (China)

^d Ezhou Central Hospital   (China)

^e SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Catenin; Colorectal cancer; NF B; PI3K

Indexed keywords

BETA CATENIN; FAS ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ANDROSTADIENES; ANTIGENS, CD95; APOPTOSIS; BETA CATENIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMONES; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; COLORECTAL NEOPLASMS; HCT116 CELLS; HUMANS; MICROSCOPY, FLUORESCENCE; MORPHOLINES; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878207220     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.03.135     Document Type: Article

References (30)

1. Kikuchi A. Roles of Axin in the Wnt signalling pathway. Cell. Signal. 1999, 11:777-788.
2. Korinek V., Barker N., Morin P.J., van Wichen D., de Weger R., Kinzler K.W., Vogelstein B., Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997, 275:1784-1787.
3. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996, 87:159-170.
4. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
5. Gustin J.P., Karakas B., Weiss M.B., Abukhdeir A.M., Lauring J., Garay J.P., Cosgrove D., Tamaki A., Konishi H., Konishi Y., Mohseni M., Wang G., Rosen D.M., Denmeade S.R., Higgins M.J., Vitolo M.I., Bachman K.E., Park B.H. Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc. Natl. Acad. Sci. USA 2009, 106:2835-2840.
6. Philp A.J., Campbell I.G., Leet C., Vincan E., Rockman S.P., Whitehead R.H., Thomas R.J., Phillips W.A. The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res. 2001, 61:7426-7429.
7. Samuels Y., Ericson K. Oncogenic PI3K and its role in cancer. Curr. Opin. Oncol. 2006, 18:77-82.
8. Bours V., Bentires-Alj M., Hellin A.C., Viatour P., Robe P., Delhalle S., Benoit V., Merville M.P. Nuclear factor-kappa B, cancer, and apoptosis. Biochem. Pharmacol. 2000, 60:1085-1089.
9. Zheng Y., Ouaaz F., Bruzzo P., Singh V., Gerondakis S., Beg A.A. NF-kappa B RelA (p65) is essential for TNF-alpha-induced fas expression but dispensable for both TCR-induced expression and activation-induced cell death. J. Immunol. 2001, 166:4949-4957.
10. Ryan K.M., Ernst M.K., Rice N.R., Vousden K.H. Role of NF-kappaB in p53-mediated programmed cell death. Nature 2000, 404:892-897.
11. Deng J., Miller S.A., Wang H.Y., Xia W., Wen Y., Zhou B.P., Li Y., Lin S.Y., Hung M.C. Beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. Cancer Cell 2002, 2:323-334.
12. Deng J., Xia W., Miller S.A., Wen Y., Wang H.Y., Hung M.C. Crossregulation of NF-kappaB by the APC/GSK-3beta/beta-catenin pathway. Mol. Carcinog. 2004, 39:139-146.
13. Morin P.J., Sparks A.B., Korinek V., Barker N., Clevers H., Vogelstein B., Kinzler K.W. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275:1787-1790.
14. Lin S.Y., Xia W., Wang J.C., Kwong K.Y., Spohn B., Wen Y., Pestell R.G., Hung M.C. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc. Natl. Acad. Sci. USA 2000, 97:4262-4266.
15. Easwaran V., Pishvaian M., Salimuddin, Byers S. Cross-regulation of beta-catenin-LEF/TCF and retinoid signaling pathways. Curr. Biol. 1999, 9:1415-1418.
16. Cully M., You H., Levine A.J., Mak T.W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 2006, 6:184-192.
17. Ng S.S., Mahmoudi T., Danenberg E., Bejaoui I., de Lau W., Korswagen H.C., Schutte M., Clevers H. Phosphatidylinositol 3-kinase signaling does not activate the wnt cascade. J. Biol. Chem. 2009, 284:35308-35313.
18. Lilien J., Balsamo J. The regulation of cadherin-mediated adhesion by tyrosine phosphorylation/dephosphorylation of beta-catenin. Curr. Opin. Cell Biol. 2005, 17:459-465.
19. Piedra J., Martinez D., Castano J., Miravet S., Dunach M., de Herreros A.G. Regulation of beta-catenin structure and activity by tyrosine phosphorylation. J. Biol. Chem. 2001, 276:20436-20443.
20. Stark L.A., Reid K., Sansom O.J., Din F.V., Guichard S., Mayer I., Jodrell D.I., Clarke A.R., Dunlop M.G. Aspirin activates the NF-kappaB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer. Carcinogenesis 2007, 28:968-976.
21. Din F.V., Dunlop M.G., Stark L.A. Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis. Br. J. Cancer 2004, 91:381-388.
22. Cho M., Gwak J., Park S., Won J., Kim D.E., Yea S.S., Cha I.J., Kim T.K., Shin J.G., Oh S. Diclofenac attenuates Wnt/beta-catenin signaling in colon cancer cells by activation of NF-kappaB. FEBS Lett. 2005, 579:4213-4218.
23. Collett G.P., Campbell F.C. Overexpression of p65/RelA potentiates curcumin-induced apoptosis in HCT116 human colon cancer cells. Carcinogenesis 2006, 27:1285-1291.
24. Du Q., Zhang X., Cardinal J., Cao Z., Guo Z., Shao L., Geller D.A. Wnt/beta-catenin signaling regulates cytokine-induced human inducible nitric oxide synthase expression by inhibiting nuclear factor-kappaB activation in cancer cells. Cancer Res. 2009, 69:3764-3771.
25. Butler L.M., Hewett P.J., Butler W.J., Cowled P.A. Down-regulation of Fas gene expression in colon cancer is not a result of allelic loss or gene rearrangement. Br. J. Cancer 1998, 77:1454-1459.
26. Moller P., Koretz K., Leithauser F., Bruderlein S., Henne C., Quentmeier A., Krammer P.H. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int. J. Cancer 1994, 57:371-377.
27. Cascino I., Papoff G., De Maria R., Testi R., Ruberti G. Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J. Immunol. 1996, 156:13-17.
28. Hughes S.J., Nambu Y., Soldes O.S., Hamstra D., Rehemtulla A., Iannettoni M.D., Orringer M.B., Beer D.G. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res. 1997, 57:5571-5578.
29. Guillen-Ahlers H., Suckow M.A., Castellino F.J., Ploplis V.A. Fas/CD95 deficiency in ApcMin/+ mice increases intestinal tumor burden. PLoS ONE 2010, 5:e9070.
30. Pryczynicz A., Guzinska-Ustymowicz K., Kemona A. Fas/FasL expression in colorectal cancer. An immunohistochemical study. Folia Histochem. Cytobiol. 2010, 48:425-429.